TP53AIP1抗体;TP53AIP1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P12017(TP53AIP1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P12017(TP53AIP1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The TP53AIP1 (Tumor Protein 53-Activated Intracellular Protein 1) antibody is a critical tool for studying the functional dynamics of the TP53AIP1 protein, a key mediator of p53-dependent apoptosis. TP53AIP1 is a nuclear-encoded mitochondrial protein transcriptionally activated by the tumor suppressor p53 in response to severe DNA damage. Its induction triggers mitochondrial membrane permeabilization, cytochrome c release, and caspase activation, ultimately promoting programmed cell death. This pathway underscores its role as a tumor suppressor, with dysregulation linked to cancer progression and chemoresistance.

Antibodies targeting TP53AIP1 enable researchers to detect and quantify its expression in cells or tissues using techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies are essential for investigating TP53AIP1's regulation, its interaction with p53 under stress conditions, and its involvement in apoptosis signaling networks. Validated antibodies typically demonstrate specificity for human TP53AIP1. though cross-reactivity with orthologs in model organisms (e.g., mice) may vary depending on epitope conservation.

Research applications span oncology, particularly in cancers with p53 mutations or defective apoptotic responses, where TP53AIP1 expression may correlate with therapeutic outcomes. Commercially available TP53AIP1 antibodies are often raised in rabbits or mice, with validation data including knockdown controls or peptide blocking assays to confirm specificity. Their use advances understanding of p53-mediated tumor suppression and supports drug discovery targeting apoptotic pathways.